hydroxyurea has been researched along with Granulocytic Leukemia in 169 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied." | 7.65 | Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. ( Cannellos, GP; Schwartz, JH, 1975) |
| "An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was performed in 93 patients treated by 32P alone (PVSG protocols) since 1970-1979, 395 patients over the age of 65 years treated by 32P with or without maintenance therapy using hydroxyurea (French protocol) since 1980-1994, and 202 patients under the age of 65 treated by either hydroxyurea or pipobroman since 1980." | 6.18 | Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". ( Dresch, C; Echard, M; Goguel, A; Grange, MJ; Lejeune, F; Najean, Y; Rain, JD, 1996) |
| "Treatment with hydroxyurea was followed by a marked reduction in spleen size, a decrease in white cell count and healing of the skin lesions." | 5.26 | Chronic granulocytic leukemia cutis treated with hydroxyurea. Report of a case. ( Atamer, MA; Friedhoff, FW; Thelmo, WL, 1978) |
| "The conventional management of patients with high-risk Philadelphia chromosome-negative (Ph-negative) myeloproliferative disorders (MPDs) revolves around the administration of cytoreductive agents such as hydroxyurea, anagrelide, and recombinant human interferon alpha (IFN-alpha)." | 4.83 | Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. ( Giles, F; Kantarjian, HM; Quintás-Cardama, A; Verstovsek, S, 2006) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "The unusual appearance of extensive skin ulcerations was observed in 17 patients with chronic myelogenous leukemia on continuous chemotherapy with hydroxyurea." | 3.67 | Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. ( Alimena, G; Carlesimo, OA; Gastaldi, R; Mandelli, F; Montefusco, E; Valesini, G, 1986) |
| "A 34% response was obtained in 202 evaluable patients in the terminal phase of chronic granulocytic leukemia using combinations of hydroxyurea, 6-mercaptopurine, and corticosteroids." | 3.66 | Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. ( Cavalli, F; Coleman, M; Glidewell, O; Holland, JF; Kostinas, JE; Pajak, TF; Rai, KR; Silver, RT, 1980) |
| "A 46-month-old boy with juvenile chronic granulocytic leukemia was treated intensively with hydroxyurea, dimethyl myleran, cyclophosphamide, and total body irradiation." | 3.66 | Successful treatment of juvenile chronic granulocytic leukemia with marrow transplantation. ( Buckner, CD; Sanders, JE; Stewart, P; Thomas, ED, 1979) |
| "The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied." | 3.65 | Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. ( Cannellos, GP; Schwartz, JH, 1975) |
| "Acetohydroxamic acid has been identified, by paper chromatography, in the blood of three patients with chronic myelogenous leukemia on hydroxyurea therapy." | 3.64 | HYDROXYUREA: MECHANISM OF ACTION. ( CARBONE, PP; FISHBEIN, WN, 1963) |
| "Calcitriol was continued as the only postremission therapy." | 2.67 | Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. ( Desforges, JF; Fogaren, T; Miller, KB; Slapak, CA, 1992) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Eight patients with M3 (acute promyelocytic leukemia) were excluded from the study." | 1.38 | Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients. ( Atkinson, HD; Colovic, M; Colovic, N; Jankovic, G; Kraguljac, N; Radojkovic, M; Stanisavljevic, D; Suvajdzic, N; Tomin, D; Vidovic, A, 2012) |
| " We conclude that valproic acid+ATRA+theophylline combined with 6-mercaptopurin or hydroxyurea can be safe and effective in palliative treatment of human AML." | 1.36 | Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases. ( Bruserud, Ø; Fredly, H; Gjertsen, BT; Stapnes Bjørnsen, C, 2010) |
| "State-of-art of aggressive treatment of acute myeloid leukemia (AML) in patients older than 60 years is one of the least satisfactory topics of present-day hematology." | 1.33 | Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy. ( Brychtova, Y; Buchtova, I; Doubek, M; Mayer, J; Palasek, I, 2005) |
| "Hydroxyurea (HU) is a competitive inhibitor of ribonucleotide reductase that is used for the treatment of myeloproliferative disorders." | 1.33 | ATR activation necessary but not sufficient for p53 induction and apoptosis in hydroxyurea-hypersensitive myeloid leukemia cells. ( Dodson, GE; Kumar, S; Puchalski, JR; Tibbetts, RS; Trinh, A, 2005) |
| "The patient who had trisomy 8 at the time of diagnosis underwent myeloid blastic transformation in 35 months." | 1.31 | Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. ( Hirose, Y; Masaki, Y; Sugai, S, 2002) |
| " A single dose of CY or four consecutive daily doses of AMSA produced increased survival in leukemic rats, with a positive-slope dose-response curve up to the maximum tolerated dose (MTD)." | 1.28 | Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model. ( Cordel, K; Holm, C; Vaughan, WP, 1989) |
| "Chronic granulocytic leukemia (CGL) developed in a 31-year-old man after he underwent a third renal transplant." | 1.27 | Chronic granulocytic leukemia after renal transplantation. ( Didlake, R; Files, JC; Kirchner, KA; Krueger, RP; Raju, S, 1983) |
| " There was no correlation between drug dosage and length of survival, whereas the disappearance of blast cells from the peripheral blood appeared to be directly correlated with a longer survival." | 1.27 | Characterization and treatment of the non-lymphoblastic crisis of chronic myelogenous leukemia. ( Annino, L; Mandelli, F; Mariani, G; Solinas, S, 1983) |
| "Chronic myelogenous leukemia was diagnosed in 7 dogs." | 1.27 | Chronic myelogenous leukemia in the dog. ( Leifer, CE; MacEwen, EG; Matus, RE; Patnaik, AK, 1983) |
| "Seventeen patients with either chronic myelogenous leukemia (CML) or myelofibrosis with myeloid metaplasia (MMM) received 24 courses of splenic irradiation at this institution from 1973 to 1982." | 1.27 | Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea. ( Desforges, J; Madoc-Jones, H; McKeough, PG; Wagner, H, 1986) |
| "Treatment with hydroxyurea and antihistamines led to resolution of the skin eruption and improvement of the pruritus." | 1.27 | Acne urticata associated with chronic myelogenous leukemia. ( Brydon, J; Duffy, T; Lucky, PA, 1985) |
| "Caracemide was found to be about twelve times more effective than hydroxyurea." | 1.27 | In vitro cytotoxicity of caracemide alone and in combination with hydroxyurea or iron-chelating agents in human chronic myeloid leukemia cells and murine tumors. ( Advani, SH; Chitnis, MP; Satyamoorthy, K, 1988) |
| " Both patients exhibited significant increases in Ph-positive cells, to 46 and 72% of marrow metaphases, during subsequent chemotherapy with hydroxyurea, in dosage sufficient to maintain granulocytopenia and a normal serum B12 level." | 1.27 | Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. ( Bigner, SH; Gockerman, JP; Sokal, JE, 1988) |
| "Busulfan was given over 4 weeks resulting in a remission of 13 years duration." | 1.27 | [24-year survival in chronic myeloid leukemia]. ( Hehlmann, R; Müller, L, 1987) |
| "Even patients with chronic myelogenous leukemia (CML) in blast crisis were treated with chemotherapy, followed by infusion of autologous bone marrow that had been collected during the chronic phase of the disease and cryopreserved at -198 degrees C." | 1.27 | Autologous marrow transplantation for patients with chronic myelogenous leukemia (CML) in blast crisis. ( Dantas, M; Drebing, C; Glode, LM; Koeppler, H; Robinson, WA; Thomas, MR, 1984) |
| "Nonspecific cutaneous xanthomas have occasionally been reported with a variety of leukemias, mostly in the pediatric literature, but the first report (to our knowledge) of acute myelomonocytic leukemia presenting with specific cutaneous xanthomatous lesions appeared in 1982." | 1.27 | Cutaneous xanthomas associated with chronic myelomonocytic leukemia. ( Adler, KR; Rothenberg, J; Vail, JT, 1985) |
| "Leucocytes from patients with chronic myelogenous leukemia had higher repair synthesis after Neocarzinostatin treatment compared to those from patients with acute leukemia." | 1.26 | DNA repair in human leukemic leucocytes treated with neocarzinostatin. ( Nakamura, T; Sasada, M; Sawada, H; Uchino, H, 1978) |
| "Treatment with hydroxyurea was followed by a marked reduction in spleen size, a decrease in white cell count and healing of the skin lesions." | 1.26 | Chronic granulocytic leukemia cutis treated with hydroxyurea. Report of a case. ( Atamer, MA; Friedhoff, FW; Thelmo, WL, 1978) |
| "In these 8 patients, factor V deficiency was not due to hepatic dysfunction, factor V inhibitors, or disseminated intravascular coagulation." | 1.26 | Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. ( Bennett, AJ; Coccia, PF; Edson, JR; Hasegawa, DK; Krivit, W; Nesbit, ME; Ramsay, NK, 1980) |
| "Cytogenetic studies of chronic myelogenous leukemia (CML) have shown that the majority of hemopoietic cells originate from pluripotential stem cells affected in this disease." | 1.26 | Philadelphia-chromosome-positive pre-B-cell leukemia presenting as blast crisis of chronic myelogenous leukemia. ( Brattain, MG; Coleman, MS; Crist, WM; Sarrif, A; Vinson, PC; Vogler, LB, 1979) |
| "Hydroxyurea treated patients who are still alive have been followed for a median period of 69 months (range, 25-136 months) and a projected median survival for periods of 56 and 90 months, respectively." | 1.26 | Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. ( Bolin, RW; Hamman, RF; Robinson, WA; Sutherland, J, 1982) |
| "Hydroxyurea was associated with less life-threatening toxicity." | 1.26 | Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. ( Gibbs, G; Goldman, A; Howe, R; Kennedy, BJ; Rushing, D, 1982) |
| "Hydroxyurea is an effective agent in the treatment of chronic myelogenous leukemia." | 1.25 | Skin changes secondary to hydroxyurea therapy. ( Goltz, RW; Kennedy, BJ; Smith, LR, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 123 (72.78) | 18.7374 |
| 1990's | 17 (10.06) | 18.2507 |
| 2000's | 22 (13.02) | 29.6817 |
| 2010's | 6 (3.55) | 24.3611 |
| 2020's | 1 (0.59) | 2.80 |
| Authors | Studies |
|---|---|
| Kockerols, CCB | 1 |
| Geelen, I | 1 |
| Levin, MD | 1 |
| Janssen, JJWM | 1 |
| Dinmohamed, AG | 1 |
| Hoogendoorn, M | 1 |
| Cornelissen, JJ | 1 |
| Westerweel, PE | 1 |
| Janakiram, M | 1 |
| Verma, A | 1 |
| Wang, Y | 1 |
| Budhathoki, A | 1 |
| Suarez Londono, J | 1 |
| Murakhovskaya, I | 1 |
| Braunschweig, I | 1 |
| Minniti, CP | 1 |
| Patel, AB | 1 |
| Chen, YH | 1 |
| Zhang, Y | 1 |
| Frankfurt, O | 1 |
| Winter, JN | 1 |
| Beer, PA | 1 |
| Green, AR | 2 |
| Lu, X | 1 |
| Ohata, K | 1 |
| Kondo, Y | 1 |
| Espinoza, JL | 1 |
| Qi, Z | 1 |
| Nakao, S | 1 |
| Fredly, H | 1 |
| Stapnes Bjørnsen, C | 1 |
| Gjertsen, BT | 1 |
| Bruserud, Ø | 1 |
| Tefferi, A | 3 |
| Colovic, M | 1 |
| Colovic, N | 1 |
| Radojkovic, M | 1 |
| Stanisavljevic, D | 1 |
| Kraguljac, N | 1 |
| Jankovic, G | 1 |
| Tomin, D | 1 |
| Suvajdzic, N | 1 |
| Vidovic, A | 1 |
| Atkinson, HD | 1 |
| Matsui, WH | 1 |
| Gladstone, DE | 1 |
| Vala, MS | 1 |
| Barber, JP | 1 |
| Brodsky, RA | 1 |
| Smith, BD | 1 |
| Jones, RJ | 1 |
| Huang, PH | 1 |
| You, JY | 1 |
| Hsu, HC | 1 |
| Bernasconi, P | 1 |
| Boni, M | 1 |
| Cavigliano, PM | 1 |
| Calatroni, S | 1 |
| Brusamolino, E | 2 |
| Passamonti, F | 1 |
| Volpe, G | 1 |
| Pistorio, A | 1 |
| Giardini, I | 1 |
| Rocca, B | 1 |
| Caresana, M | 1 |
| Lazzarino, M | 2 |
| Bernasconi, C | 2 |
| Binder, WD | 1 |
| Brown, DF | 1 |
| Nadel, ES | 1 |
| Petti, MC | 2 |
| Tafuri, A | 1 |
| Latagliata, R | 1 |
| Aloe Spiriti, MA | 1 |
| Montefusco, E | 3 |
| Mancini, M | 1 |
| Meloni, G | 1 |
| Petrucci, MT | 1 |
| Spadea, A | 2 |
| Redi, R | 1 |
| Alimena, G | 3 |
| Mandelli, F | 6 |
| FISHBEIN, WN | 1 |
| CARBONE, PP | 1 |
| SHULLENBERGER, CC | 1 |
| KRAKOFF, IH | 1 |
| SAVEL, H | 1 |
| MURPHY, ML | 1 |
| Cazzola, M | 1 |
| Barbui, T | 1 |
| Barosi, G | 1 |
| Grossi, A | 1 |
| Gugliotta, L | 1 |
| Liberato, LN | 1 |
| Marchetti, M | 1 |
| Mazzucconi, MG | 1 |
| Rodeghiero, F | 1 |
| Tura, S | 4 |
| Geraminejad, PA | 1 |
| Walling, HW | 1 |
| Swick, BL | 1 |
| Sontheimer, RD | 1 |
| Riccioni, R | 1 |
| Pasquini, L | 1 |
| Mariani, G | 2 |
| Saulle, E | 1 |
| Rossini, A | 1 |
| Diverio, D | 1 |
| Pelosi, E | 1 |
| Vitale, A | 1 |
| Chierichini, A | 1 |
| Cedrone, M | 1 |
| Foà, R | 1 |
| Lo Coco, F | 1 |
| Peschle, C | 1 |
| Testa, U | 1 |
| Doubek, M | 1 |
| Palasek, I | 1 |
| Brychtova, Y | 1 |
| Buchtova, I | 1 |
| Mayer, J | 1 |
| Chim, CS | 1 |
| Ma, SK | 1 |
| Kumar, S | 1 |
| Dodson, GE | 1 |
| Trinh, A | 1 |
| Puchalski, JR | 1 |
| Tibbetts, RS | 1 |
| Perel, JM | 1 |
| McCarthy, C | 1 |
| Walker, O | 1 |
| Irving, I | 1 |
| Williams, B | 1 |
| Kennedy, GA | 1 |
| Neynaber, S | 1 |
| Wolff, H | 1 |
| Plewig, G | 1 |
| Wienecke, R | 1 |
| Yin, CC | 1 |
| Cortes, J | 1 |
| Barkoh, B | 1 |
| Hayes, K | 1 |
| Kantarjian, H | 2 |
| Jones, D | 1 |
| Quintás-Cardama, A | 1 |
| Kantarjian, HM | 3 |
| Giles, F | 1 |
| Verstovsek, S | 1 |
| Burnett, AK | 1 |
| Milligan, D | 1 |
| Prentice, AG | 1 |
| Goldstone, AH | 1 |
| McMullin, MF | 1 |
| Hills, RK | 1 |
| Wheatley, K | 1 |
| Mey, U | 1 |
| Kiss, A | 1 |
| Jakó, J | 1 |
| Rák, K | 1 |
| Fleischer, J | 2 |
| Franke, WG | 1 |
| Rauscher, F | 1 |
| Cadman, E | 1 |
| Spiers, AS | 1 |
| Sigal, M | 1 |
| Crickx, B | 1 |
| Blanchet, P | 1 |
| Perron, J | 1 |
| Simony, J | 1 |
| Belaïch, S | 1 |
| Kirchner, KA | 1 |
| Files, JC | 1 |
| Didlake, R | 1 |
| Raju, S | 1 |
| Krueger, RP | 1 |
| Baker, MA | 1 |
| Taub, RN | 1 |
| Carter, WH | 1 |
| Davidson, M | 1 |
| Sutton, DM | 1 |
| Kutas, G | 1 |
| Berger, S | 1 |
| Watt, HJ | 1 |
| Thomas, MR | 1 |
| Robinson, WA | 2 |
| Dantas, M | 1 |
| Koeppler, H | 1 |
| Drebing, C | 1 |
| Glode, LM | 1 |
| Garciá-Conde, J | 1 |
| Alberola, V | 1 |
| Lluch, A | 1 |
| Escrig, V | 1 |
| Kubota, K | 1 |
| Preisler, HD | 1 |
| Costanzo, C | 1 |
| Leifer, CE | 1 |
| Matus, RE | 1 |
| Patnaik, AK | 1 |
| MacEwen, EG | 1 |
| Petri, M | 1 |
| Ellman, L | 1 |
| Carey, R | 1 |
| Hibbin, JA | 1 |
| McCarthy, DM | 1 |
| Goldman, JM | 1 |
| Haas, OA | 1 |
| Schwarzmeier, JD | 2 |
| Nacheva, E | 1 |
| Fischer, P | 2 |
| Paietta, E | 2 |
| Annino, L | 1 |
| Solinas, S | 1 |
| Solal-Celigny, P | 1 |
| Desaint, B | 1 |
| Herrera, A | 1 |
| Chastang, C | 1 |
| Amar, M | 1 |
| Vroclans, M | 1 |
| Brousse, N | 1 |
| Mancilla, F | 1 |
| Renoux, M | 1 |
| Bernard, JF | 1 |
| Porzsolt, F | 1 |
| Gröger, G | 1 |
| Vogel, W | 1 |
| Heimpel, H | 2 |
| Hester, JP | 2 |
| Waddell, CC | 1 |
| Coltman, CA | 1 |
| Morrison, FS | 1 |
| Stephens, RL | 1 |
| Balcerzak, SP | 1 |
| Baker, LH | 1 |
| Chen, TT | 1 |
| Haas, O | 1 |
| Mehta, BC | 2 |
| Agarwal, MB | 2 |
| Coleman, M | 1 |
| Silver, RT | 1 |
| Pajak, TF | 1 |
| Cavalli, F | 2 |
| Rai, KR | 1 |
| Kostinas, JE | 1 |
| Glidewell, O | 1 |
| Holland, JF | 1 |
| Lotem, J | 2 |
| Sachs, L | 2 |
| Dresch, C | 2 |
| Faille, A | 1 |
| Poirier, O | 1 |
| Balitrand, N | 1 |
| Najean, Y | 2 |
| Rushing, D | 1 |
| Goldman, A | 1 |
| Gibbs, G | 1 |
| Howe, R | 1 |
| Kennedy, BJ | 5 |
| Bolin, RW | 1 |
| Sutherland, J | 1 |
| Hamman, RF | 1 |
| Lamas, S | 1 |
| Sanjuán, I | 1 |
| Zabala, P | 1 |
| Millán, I | 1 |
| Cabrera, R | 1 |
| Barbolla, L | 1 |
| Menéndez, J | 1 |
| Fernández, MN | 1 |
| Klener, P | 1 |
| Donner, L | 1 |
| Hasegawa, DK | 1 |
| Bennett, AJ | 1 |
| Coccia, PF | 1 |
| Ramsay, NK | 1 |
| Nesbit, ME | 1 |
| Krivit, W | 1 |
| Edson, JR | 1 |
| Petukhov, VI | 1 |
| Inhorn, RC | 1 |
| Aster, JC | 1 |
| Roach, SA | 1 |
| Slapak, CA | 2 |
| Soiffer, R | 1 |
| Tantravahi, R | 1 |
| Stone, RM | 1 |
| Gómez-Casares, MT | 1 |
| Delgado, MD | 1 |
| Lerga, A | 1 |
| Crespo, P | 1 |
| Quincoces, AF | 1 |
| Richard, C | 1 |
| León, J | 1 |
| Dosil, M | 1 |
| Alvarez-Fernández, L | 1 |
| Gómez-Márquez, J | 1 |
| Furgerson, JL | 1 |
| Vukelja, SJ | 1 |
| Baker, WJ | 1 |
| O'Rourke, TJ | 1 |
| Leszczynski, D | 1 |
| Rain, JD | 1 |
| Goguel, A | 1 |
| Lejeune, F | 1 |
| Echard, M | 1 |
| Grange, MJ | 1 |
| Sánchez Fayos, J | 1 |
| Román Barbero, A | 1 |
| Nevado Reviriego, I | 1 |
| Sterkers, Y | 1 |
| Preudhomme, C | 1 |
| Laï, JL | 1 |
| Demory, JL | 1 |
| Caulier, MT | 1 |
| Wattel, E | 1 |
| Bordessoule, D | 1 |
| Bauters, F | 1 |
| Fenaux, P | 1 |
| Cacciola, E | 2 |
| Cacciola, RR | 1 |
| Guglielmo, P | 1 |
| Stagno, F | 1 |
| Giustolisi, R | 1 |
| Silverstein, MN | 1 |
| Rocamora, V | 1 |
| Puig, L | 1 |
| Alomar, A | 1 |
| Fazi, F | 1 |
| Cordone, I | 1 |
| Ariola, C | 1 |
| Nanni, M | 1 |
| Spiriti, MA | 1 |
| Fenu, S | 1 |
| Bauer, HI | 1 |
| Kaatz, M | 1 |
| Elsner, P | 1 |
| Hirose, Y | 1 |
| Masaki, Y | 1 |
| Sugai, S | 1 |
| Sasada, M | 1 |
| Sawada, H | 1 |
| Nakamura, T | 1 |
| Uchino, H | 1 |
| Tschopp, L | 1 |
| Alberto, P | 1 |
| Martz, G | 1 |
| Friedhoff, FW | 1 |
| Atamer, MA | 1 |
| Thelmo, WL | 1 |
| Cunningham, I | 1 |
| Gee, T | 1 |
| Dowling, M | 1 |
| Chaganti, R | 1 |
| Bailey, R | 1 |
| Hopfan, S | 1 |
| Bowden, L | 1 |
| Turnbull, A | 1 |
| Knapper, W | 1 |
| Clarkson, B | 2 |
| Pralle, H | 2 |
| Löffler, H | 2 |
| Inbal, A | 1 |
| Modan, M | 1 |
| Many, A | 1 |
| Berg, J | 1 |
| Vincent, PC | 2 |
| Gunz, FW | 2 |
| Vogler, LB | 1 |
| Crist, WM | 1 |
| Vinson, PC | 1 |
| Sarrif, A | 1 |
| Brattain, MG | 1 |
| Coleman, MS | 1 |
| Sanders, JE | 1 |
| Buckner, CD | 1 |
| Stewart, P | 1 |
| Thomas, ED | 1 |
| Izui, S | 1 |
| Lambert, PH | 1 |
| Carpentier, N | 1 |
| Miescher, PA | 1 |
| Canellos, GP | 4 |
| Brodsky, I | 1 |
| Fuscaldo, KE | 1 |
| Kahn, SB | 1 |
| Conroy, JF | 1 |
| Lamping, CG | 1 |
| Whang-Peng, J | 1 |
| Broder, S | 1 |
| Lee, E | 1 |
| Young, RC | 2 |
| Smith, LR | 1 |
| Goltz, RW | 1 |
| Schwartz, JH | 1 |
| Cannellos, GP | 1 |
| Yataganas, X | 2 |
| Strife, A | 1 |
| Perez, A | 1 |
| Baccarani, M | 2 |
| Zaccaria, A | 1 |
| Santucci, AM | 1 |
| Bagnara, GP | 1 |
| Ricci, P | 1 |
| Gobbi, M | 1 |
| Ruggero, D | 1 |
| Brunelli, MA | 1 |
| Desforges, JF | 1 |
| Fogaren, T | 1 |
| Miller, KB | 1 |
| Colly, LP | 1 |
| Richel, DJ | 1 |
| Arentsen-Honders, MW | 1 |
| Kester, MG | 1 |
| ter Riet, PM | 1 |
| Willemze, R | 1 |
| Bhalla, K | 1 |
| Swerdlow, P | 1 |
| Grant, S | 1 |
| Kramer, ZB | 1 |
| Boros, L | 1 |
| Wiernik, PH | 1 |
| Andersen, J | 1 |
| Bennett, JM | 1 |
| Cassileth, P | 1 |
| Oken, M | 1 |
| Zittoun, J | 2 |
| Marquet, J | 2 |
| David, JC | 1 |
| Wagner, H | 1 |
| McKeough, PG | 1 |
| Desforges, J | 1 |
| Madoc-Jones, H | 1 |
| Koller, CA | 1 |
| Miller, DM | 1 |
| Talpaz, M | 3 |
| Kurzrock, R | 1 |
| Keating, MJ | 2 |
| McCredie, KB | 2 |
| Gutterman, J | 2 |
| Freireich, EJ | 2 |
| Champlin, RE | 1 |
| Golde, DW | 1 |
| Yoffe, G | 1 |
| Blick, M | 1 |
| Spitzer, G | 1 |
| Vaughan, WP | 1 |
| Holm, C | 1 |
| Cordel, K | 1 |
| Blanc, AP | 1 |
| Cebe, G | 1 |
| Jullien-Depradeux, AM | 1 |
| Taillan, B | 1 |
| Pedinielli, FJ | 1 |
| Routy, JP | 1 |
| Carcassonne, Y | 1 |
| Queisser, W | 2 |
| Herrmann, F | 1 |
| Lindemann, A | 1 |
| Anger, B | 4 |
| Hiddemann, W | 1 |
| Krey, U | 1 |
| Hecht, F | 1 |
| Morgan, R | 1 |
| Schrier, SL | 1 |
| Adams, J | 1 |
| Sandberg, AA | 1 |
| Ostendorf, P | 1 |
| Ehninger, G | 1 |
| Schmidt, H | 1 |
| Haen, M | 1 |
| Link, H | 1 |
| Schüch, K | 1 |
| Müller, C | 1 |
| Wernet, P | 1 |
| Dopfer, H | 1 |
| Klingebiel, T | 1 |
| Satyamoorthy, K | 3 |
| Chitnis, MP | 3 |
| Basrur, VS | 2 |
| Advani, SH | 3 |
| Brydon, J | 1 |
| Lucky, PA | 1 |
| Duffy, T | 1 |
| Blonk, MC | 1 |
| Ossenkoppele, GJ | 1 |
| Sokal, JE | 2 |
| Gockerman, JP | 1 |
| Bigner, SH | 1 |
| Hehlmann, R | 4 |
| Messerer, D | 2 |
| Zankovich, R | 2 |
| Bergmann, L | 3 |
| Kolb, HJ | 3 |
| Meyer, P | 2 |
| Essers, U | 2 |
| Queisser, U | 2 |
| Vaupel, H | 2 |
| Hossfeld, DK | 1 |
| Köpcke, W | 1 |
| Okabe-Kado, J | 1 |
| Hayashi, M | 1 |
| Honma, Y | 1 |
| Hozumi, M | 1 |
| Hashimi, L | 1 |
| Al-Katib, A | 1 |
| Mertelsmann, R | 1 |
| Mohamed, AN | 1 |
| Koziner, B | 1 |
| Ross, J | 1 |
| Peltz, SW | 1 |
| Kobs, G | 1 |
| Brewer, G | 1 |
| Pradhan, SG | 1 |
| Müller, L | 1 |
| Sylvester, RK | 1 |
| Lobell, M | 1 |
| Teresi, ME | 1 |
| Brundage, D | 1 |
| Dubowy, R | 1 |
| Gastaldi, R | 1 |
| Carlesimo, OA | 1 |
| Valesini, G | 1 |
| Morra, E | 1 |
| Inverardi, D | 1 |
| Castelli, G | 1 |
| Merante, S | 1 |
| Griffin, JD | 1 |
| Lemoine, F | 1 |
| Najman, A | 1 |
| Laporte, JP | 1 |
| Gorin, NC | 1 |
| Duhamel, G | 1 |
| Moreb, J | 1 |
| Hershko, C | 1 |
| Zittoun, R | 1 |
| Marie, JP | 1 |
| Haanen, C | 1 |
| Vail, JT | 1 |
| Adler, KR | 1 |
| Rothenberg, J | 1 |
| Hasselbalch, H | 1 |
| Birgens, HS | 1 |
| Geisler, C | 1 |
| Hansen, NE | 1 |
| Smith, TL | 1 |
| Walters, RS | 1 |
| Bligham, G | 1 |
| Gehan, E | 1 |
| Burchenal, JH | 1 |
| Carter, SK | 2 |
| Clarkson, BD | 1 |
| Schwarzenberg, L | 4 |
| Mathe, G | 4 |
| Pouillart, P | 2 |
| Weiner, R | 2 |
| Lacour, J | 1 |
| Genin, J | 2 |
| Schneider, M | 4 |
| de Vassal, F | 2 |
| Hayat, M | 2 |
| Amiel, JL | 3 |
| Schlumberger, JR | 4 |
| Jasmin, C | 2 |
| Rosenfeld, C | 2 |
| Cerny, V | 1 |
| Koza, I | 1 |
| Halko, J | 1 |
| Bohunicky, L | 1 |
| Krizan, Z | 1 |
| Poliakova, L | 1 |
| Petrek, C | 1 |
| Papa, G | 1 |
| Amadori, S | 2 |
| Monarca, B | 1 |
| Esposito, A | 1 |
| Cajozzo, A | 1 |
| di Marco, P | 1 |
| Panzacchi, G | 2 |
| Musso, R | 1 |
| Alberti, A | 1 |
| Magro, S | 1 |
| Rossi Ferrini, P | 1 |
| Leoni, F | 1 |
| Salti, F | 1 |
| Basetta, E | 1 |
| Monfardini, S | 1 |
| Buonanno, G | 1 |
| Rizzoli, V | 1 |
| Carnevali, C | 1 |
| Lucarelli, G | 1 |
| Porcellini, A | 1 |
| Torlontano, G | 1 |
| Fioritoni, G | 1 |
| Cattan, A | 2 |
| Amiel, JJ | 1 |
| Gluckman, E | 1 |
| Perreau, P | 1 |
| Gardais, J | 1 |
| Levi, JA | 1 |
| Huguley, CM | 1 |
| Locour, J | 1 |
| Bloomfield, CD | 1 |
| Brunning, RD | 1 |
| Theologides, A | 1 |
| Gergely, P | 1 |
| Szabó, G | 1 |
| Szegedi, G | 1 |
| Fekete, B | 1 |
| Petrányi, G | 1 |
| De Vita, VT | 1 |
| Schein, P | 1 |
| Chabner, B | 1 |
| Tanzer, J | 1 |
| Jacquillat, C | 1 |
| Weil, M | 1 |
| Briére, J | 1 |
| Bussel, A | 1 |
| Boiron, M | 1 |
| Bernard, J | 1 |
| Schreibman, SM | 1 |
| Gee, TS | 1 |
| Grabstald, H | 1 |
| Delage, C | 1 |
| Lagacé, R | 1 |
| Patel, D | 1 |
| Mason, JE | 1 |
| DeVita, VT | 1 |
| Stryckmans, PA | 1 |
| Galton, DA | 1 |
| Pensabene, A | 1 |
| Cipriani, D | 1 |
| Quaglino, D | 1 |
| Torelli, U | 1 |
| Emilia, G | 1 |
| Podos, SM | 1 |
| Shaw, S | 1 |
| Wilson, JF | 1 |
| Johnson, RE | 1 |
| Djaldetti, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over[NCT00005823] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1998-12-31 | Completed | ||
| A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than[NCT04687761] | Phase 1/Phase 2 | 84 participants (Anticipated) | Interventional | 2020-11-04 | Recruiting | ||
| The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients[NCT01633099] | Phase 3 | 46 participants (Anticipated) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for hydroxyurea and Granulocytic Leukemia
| Article | Year |
|---|---|
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria | 2004 |
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Myeloproliferative | 2006 |
Chronic granulocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantati | 1984 |
[Conventional and aggressive chemo-radiotherapy of chronic granulocytic leukemia in its different phases. Other therapeutic problems].
Topics: Anticoagulants; Antineoplastic Agents; Busulfan; Chromosomes, Human, 21-22 and Y; Clone Cells; Combi | 1984 |
[Chromosome analysis and TdT determination: important prognostic parameters of blastic crises in chronic myelocytic leukemia].
Topics: Busulfan; Chromosome Aberrations; Cytarabine; DNA Nucleotidylexotransferase; DNA Nucleotidyltransfer | 1982 |
[Splenectomy in myelocytic leukemia].
Topics: Adolescent; Adult; Aged; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid; Middle Aged; Pos | 1980 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
[Efficacious treatment of a fatal blood disease: polycythemia vera].
Topics: Acute Disease; Alkylating Agents; Busulfan; Chlorambucil; Humans; Hydroxyurea; Leukemia, Myeloid; Le | 1997 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
The pathogenesis and management of essential thrombocythaemia.
Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; He | 1999 |
Chronic granulocytic leukemia.
Topics: Alkaline Phosphatase; Blood Transfusion; Busulfan; Chromosomes, Human, 21-22 and Y; Humans; Hydroxyu | 1976 |
Chronic myelogenous leukemia: recent advances.
Topics: Bone Marrow Transplantation; Busulfan; Cell Transformation, Neoplastic; Chromosomes, Human, 21-22 an | 1985 |
Management of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Hematopoiesis | 1986 |
New cancer chemotherapeutic agents.
Topics: Aldehydes; Amides; Amines; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Azaguanine; Bl | 1972 |
Current concepts in the treatment of chronic myelocytic leukemia.
Topics: Antineoplastic Agents; Blood Platelet Disorders; Bromine; Busulfan; Dose-Response Relationship, Drug | 1973 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
Current concepts in chronic myelogenous leukemia.
Topics: Alkaline Phosphatase; Blood; Bone Marrow Cells; Bone Marrow Examination; Busulfan; Cell Division; Ce | 1974 |
Chemotherapy of chronic myelocytic leukemia.
Topics: Blood Cell Count; Bone Marrow Diseases; Busulfan; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Le | 1969 |
15 trials available for hydroxyurea and Granulocytic Leukemia
| Article | Year |
|---|---|
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hyd | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hyd | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hyd | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hyd | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hyd | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hyd | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hyd | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hyd | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hyd | 2007 |
Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase.
Topics: Adult; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Follow-Up Studies; Humans; Hyd | 1984 |
Response of chronic myelogenous leukemia patients to COAP-splenectomy. A Southwest Oncology Group study.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; C | 1984 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
[Combination chemotherapy in acute blast crisis of chronic myeloid leukaemia (author's transl)].
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myeloid; | 1977 |
A clinical trial of early splenectomy, hydroxyurea, and cyclic arabinosyl cytosine, vincristine, and prednisone in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Drug Evaluatio | 1975 |
Chronic myelogenous leukemia: a clinical and experimental evaluation of splenectomy and intensive chemotherapy.
Topics: Adult; Antineoplastic Agents; Busulfan; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Cli | 1975 |
Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol.
Topics: Acute Disease; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Bone Marrow; Calcitriol; | 1992 |
13-cis-retinoic acid in the treatment of elderly patients with acute myeloid leukemia. A phase II pilot study of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Drug Evaluation; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count; P | 1991 |
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.
Topics: Busulfan; Clinical Trials as Topic; Humans; Hydroxyurea; Interferon Type I; Leukemia, Myeloid; Middl | 1988 |
[Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897].
Topics: Busulfan; Clinical Trials as Topic; Germany, West; Humans; Hydroxyurea; Interferon Type I; Leukemia, | 1988 |
[Prospective controlled study of therapy of chronic myeloid leukemia (CML)].
Topics: Adult; Aged; Busulfan; Clinical Trials as Topic; Humans; Hydroxyurea; Interferon Type I; Leukemia, M | 1987 |
Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Hyd | 1986 |
New trends in the management of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Bromine; Busulfan; Clinical Trials as Topic; Humans; Hydroxyurea; Leukemia, M | 1972 |
Hydroxyurea therapy in chronic myelogenous leukemia.
Topics: Bone Marrow; Bone Marrow Cells; Busulfan; Clinical Trials as Topic; Drug Resistance; Humans; Hydroxy | 1972 |
134 other studies available for hydroxyurea and Granulocytic Leukemia
| Article | Year |
|---|---|
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era.
Topics: Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Protein Ki | 2022 |
Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Antineoplastic Agents; Cell Transformation, Neoplastic; F | 2018 |
Achievement of morphologic and cytogenetic remission with single-agent hydroxyurea in a patient with acute myeloid leukemia with inv(16).
Topics: Acute Disease; Antineoplastic Agents; Chromosome Inversion; Core Binding Factor beta Subunit; Gene O | 2015 |
Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis.
Topics: Caffeine; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Synergism; Gene Expression Regulation, L | 2010 |
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Hist | 2010 |
Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Compon | 2012 |
The role of growth factors in the activity of pharmacological differentiation agents.
Topics: Acute Disease; Antigens, CD; Antineoplastic Agents; Apoptosis; Bryostatins; Cell Cycle; Cell Differe | 2002 |
Extensive pulmonary infiltration by leukemic blasts successfully treated with hydroxyurea--a case report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Blast Crisis; Diagnosis, Differential; Humans; Hydroxyu | 2002 |
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Female; Humans; H | 2002 |
Blurred vision, epistaxis, and fever in a young man.
Topics: Acute Disease; Adult; Allopurinol; Antimetabolites; Antineoplastic Agents; Epistaxis; Fever; Fluid T | 2002 |
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cytogenetic Analysis; Dose-Response Relat | 2003 |
HYDROXYUREA: MECHANISM OF ACTION.
Topics: Blood Chemical Analysis; Chromatography; Humans; Hydroxamic Acids; Hydroxyurea; Leukemia; Leukemia, | 1963 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: LEUKEMIA.
Topics: Antineoplastic Agents; Drug Therapy; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; L | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: CLINICAL EVALUATION.
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leu | 1964 |
Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices.
Topics: Adult; Cohort Studies; Disease Progression; Evidence-Based Medicine; Expert Testimony; Female; Hemor | 2004 |
Chronic penile ulceration in a 72-year-old man.
Topics: Aged; Antineoplastic Agents; Chronic Disease; Diagnosis, Differential; Drug Eruptions; Hand Dermatos | 2004 |
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Diffe | 2005 |
Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2005 |
Der(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior treatment.
Topics: Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Hu | 2005 |
ATR activation necessary but not sufficient for p53 induction and apoptosis in hydroxyurea-hypersensitive myeloid leukemia cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Drug Resis | 2005 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamid | 2005 |
[Longitudinal melanonychia induced by hydroxyurea therapy].
Topics: Aged; Aged, 80 and over; Diagnosis, Differential; Female; Humans; Hydroxyurea; Hyperpigmentation; Le | 2004 |
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Marrow; Chromosomes, Human | 2006 |
[Therapy of chronic myeloid leukemia].
Topics: Busulfan; Chromosomes, Human, 21-22 and Y; Drug Administration Schedule; Humans; Hydroxyurea; Leukem | 1981 |
[The use of hydroxyurea (Biosuppressin) in the accelerated phase of chronic myeloid leukemia].
Topics: Adult; Aged; Blood Platelets; Bone Marrow; Cell Cycle; Female; Humans; Hydroxyurea; Leukemia, Myeloi | 1981 |
[Diagnosis and therapy of chronic monocytic leukemia].
Topics: Aged; Chromosome Aberrations; Colloids; Diagnosis, Differential; Female; Humans; Hydroxyurea; Indium | 1981 |
Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity.
Topics: Animals; Arabinofuranosylcytosine Triphosphate; Cell Line; Cell Survival; Cytarabine; Cytidine Triph | 1983 |
[Cutaneous lesions induced by long-term use of hydroxyurea].
Topics: Aged; Drug Eruptions; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Time Factor | 1984 |
Chronic granulocytic leukemia after renal transplantation.
Topics: Adult; Allopurinol; Azathioprine; Humans; Hydroxyurea; Kidney Transplantation; Leukemia, Myeloid; Ma | 1983 |
Autologous marrow transplantation for patients with chronic myelogenous leukemia (CML) in blast crisis.
Topics: Adult; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Doxorubicin; Female; Freezing; Humans; | 1984 |
Effects of S-phase-specific agents on granulocyte-macrophage and erythroid progenitor cells obtained from normal individuals and from patients with chronic myelogenous leukemia.
Topics: Adult; Aged; Bone Marrow Cells; Cytarabine; Female; Granulocytes; Hematopoietic Stem Cells; Humans; | 1983 |
Chronic myelogenous leukemia in the dog.
Topics: Animals; Biopsy, Needle; Blood Cell Count; Bone Marrow; Cytodiagnosis; Dog Diseases; Dogs; Drug Ther | 1983 |
Acquired factor XIII deficiency with chronic myelomonocytic leukemia.
Topics: Aged; Factor XIII Deficiency; Female; Hematoma; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Co | 1983 |
Antigenic expression and proliferative status of multilineage myeloid progenitor cells (CFU-GEMM) in normal individuals and patients with chronic granulocytic leukaemia.
Topics: Antibodies, Monoclonal; Bone Marrow Cells; Cell Division; Hematopoietic Stem Cells; Histocompatibili | 1983 |
Investigations on karyotype evolution in patients with chronic myeloid leukemia (CML).
Topics: Adult; Aged; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Female; Humans; Hydroxyurea; K | 1984 |
Characterization and treatment of the non-lymphoblastic crisis of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Female; | 1983 |
Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases.
Topics: Aged; Bone Marrow; Cell Transformation, Neoplastic; Cytarabine; Female; Humans; Hydroxyurea; Leukemi | 1984 |
Variations in the susceptibility to lysis of NK target cells.
Topics: Adult; Cell Cycle; Cell Division; Cell Line; Cell Survival; Humans; Hydroxyurea; Interphase; Killer | 1984 |
Cyclic oscillations in leukocyte count in chronic myeloid leukemia.
Topics: Biological Clocks; Busulfan; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count | 1980 |
Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies.
Topics: Daunorubicin; Dexamethasone; Drug Therapy, Combination; Gastrointestinal Diseases; Hemorrhage; Human | 1980 |
Potential pre-screening for therapeutic agents that induce differentiation in human myeloid leukemia cells.
Topics: Antineoplastic Agents; Bromodeoxyuridine; Cell Line; Cell Transformation, Neoplastic; Complement C3; | 1980 |
Bone marrow cell kinetics and culture in chronic and subacute myelomonocytic leukemia. Physiopathological interpretation and prognostic importance.
Topics: Aged; Bone Marrow; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Erythropoiesis; Human | 1980 |
Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Busulfan; Child; Female; Humans; Hydroxyurea; Leukemia, | 1982 |
Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, | 1982 |
[Chronic myeloid leukaemia. Clinical study and analysis of therapeutical results in 55 cases].
Topics: Adult; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leuk | 1982 |
Hydroxyurea therapy in chronic myeloid leukemia.
Topics: Busulfan; Humans; Hydroxyurea; Leukemia, Myeloid | 1982 |
Hydroxyurea (Biosupressin-BIOGAL) for the treatment of chronic myelogenous leukaemia.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged | 1981 |
Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Blood Coagulation Tests; Blood Transfusion; Bone Marrow Transplantation; Ch | 1980 |
Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells.
Topics: Cell Differentiation; Cell Division; Cytarabine; Down-Regulation; Erythrocytes; Gene Expression Regu | 1993 |
Differentiation-linked expression of prothymosin alpha gene in human myeloid leukemic cells.
Topics: Cell Differentiation; Down-Regulation; Humans; Hydroxyurea; Leukemia, Myeloid; Protein Precursors; R | 1993 |
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
Topics: Acute Disease; Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Thr | 1996 |
Regulation of cell cycle and apoptosis by protein kinase C in rat myeloid leukemia cell line.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; DNA; Enzyme Inhibitors; Flow Cytom | 1995 |
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Topics: Adult; Aged; Antisickling Agents; Chromosomes, Human, Pair 17; Female; Gene Deletion; Humans; Hydrox | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea.
Topics: Acute Disease; Antisickling Agents; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Polyc | 1999 |
Dermatomyositis-like eruption following hydroxyurea therapy.
Topics: Antineoplastic Agents; Dermatomyositis; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; S | 2000 |
Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leuk | 2001 |
[Circumscribed hypertrichosis lanuginosa in acute myeloid leukemia].
Topics: Acute Disease; Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Fatal Outcome; Humans; Hydroxyurea; | 2001 |
Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Busulfan; Cell Transformation, Neoplastic; Chromosomes, | 2002 |
Control of normal differentiation of myeloid leukemic cells. VI. Inhibition of cell multiplication and the formation of macrophages.
Topics: Animals; Blood; Bromodeoxyuridine; Cell Adhesion; Cell Differentiation; Cell Division; Cell Movement | 1975 |
DNA repair in human leukemic leucocytes treated with neocarzinostatin.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; DNA Repair; Dose-Response Relationship, Drug; Female | 1978 |
Chronic granulocytic leukemia cutis treated with hydroxyurea. Report of a case.
Topics: Female; Humans; Hydroxyurea; Leukemia, Myeloid; Middle Aged; Primary Myelofibrosis; Punctures; Skin | 1978 |
Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).
Topics: Adolescent; Adult; Asparaginase; Cell Transformation, Neoplastic; Chromosomes, Human, 21-22 and Y; C | 1979 |
[Experience in acceleration and blastic crisis in chronic myelocytic leukemia].
Topics: Adult; Blood Cells; Cell Count; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Methotrexate; | 1978 |
A retrospective study of patients with chronic myeloid leukemia diagnosed and treated at the Chaim Sheba Medical Center during the years 1966-76.
Topics: Busulfan; Humans; Hydroxyurea; Leukemia, Myeloid; Prognosis; Retrospective Studies | 1978 |
Extreme leucocytosis and prognosis of newly diagnosed patients with acute non-lymphocytic leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hu | 1979 |
[Splenectomy and polychemotherapy in chronic myelosis].
Topics: Busulfan; Cytarabine; Daunorubicin; Humans; Hydroxyurea; Leukemia, Myeloid; Mercaptopurine; Methotre | 1979 |
Philadelphia-chromosome-positive pre-B-cell leukemia presenting as blast crisis of chronic myelogenous leukemia.
Topics: B-Lymphocytes; Cell Transformation, Neoplastic; Child; Chromosomes, Human, 21-22 and Y; Humans; Hydr | 1979 |
Successful treatment of juvenile chronic granulocytic leukemia with marrow transplantation.
Topics: Bone Marrow Transplantation; Busulfan; Child, Preschool; Cyclophosphamide; Humans; Hydroxyurea; Leuk | 1979 |
The occurrence of antibodies against single-stranded DNA in the sera of patients with acute and chronic leukaemia.
Topics: Antibodies, Neoplasm; BCG Vaccine; DNA, Single-Stranded; Female; Follow-Up Studies; Humans; Hydroxyu | 1976 |
Unusual clonal evolution in a case of chronic myelogenous leukemia.
Topics: Adult; Chromosome Aberrations; Clone Cells; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Translocat | 1976 |
Skin changes secondary to hydroxyurea therapy.
Topics: Administration, Oral; Adult; Biopsy; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count | 1975 |
Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia.
Topics: Busulfan; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count; Leukocytosis; Mitobronitol; Splen | 1975 |
Cell kill kinetics with hydroxyurea.
Topics: Cell Count; Cell Line; Cell Survival; DNA Replication; Humans; Hydroxyurea; Leukemia, Myeloid; Mitos | 1976 |
A simultaneous study of bone marrow, spleen, and liver in chronic myeloid leukemia: evidence for differences in cell composition and karyotypes.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Cells; Cell Count; Cytarabine; Erythroblasts; Erythrocyt | 1975 |
Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway.
Topics: Cell Division; Cytarabine; Deoxycytidine Kinase; Deoxycytosine Nucleotides; DNA; Drug Resistance; Hu | 1992 |
Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cell Cycle; Cell Survival; Cytarabine; DNA; Drug Resistance; | 1991 |
Mechanism of inhibition of DNA ligase in Ara-C treated cells.
Topics: Adenosine Monophosphate; Arabinofuranosylcytosine Triphosphate; Cytarabine; DNA Ligases; Humans; Hyd | 1991 |
Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea.
Topics: Adult; Aged; Child; Evaluation Studies as Topic; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Mal | 1986 |
Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; DNA; Drug Administration Schedu | 1986 |
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Drug Evaluat | 1987 |
Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia.
Topics: Adult; Bone Marrow; Clone Cells; Combined Modality Therapy; DNA, Neoplasm; Female; Humans; Hydroxyur | 1987 |
Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model.
Topics: Amsacrine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response | 1989 |
[Association of Biermer's anemia with chronic myeloid leukemia. A case report].
Topics: Anemia, Pernicious; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Melphalan; Middle Aged | 1985 |
Therapy of the blast phase of chronic granulocytic leukemia with mithramycin and hydroxyurea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Female; Follow-Up Studies | 1988 |
The Philadelphia (Ph) chromosome in leukemia. I. A new mechanism due to interstitial deletion and insertion in chronic myelocytic leukemia.
Topics: Bone Marrow; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, 21-22 and Y; Chromosomes, | 1985 |
[Bone marrow transplantation in chronic myeloid leukemia. Influence of gnotobiotic measures, especially antiviral prophylaxis].
Topics: Acyclovir; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclos | 1986 |
Potentiation of hydroxyurea cytotoxicity in human chronic myeloid leukemia cells by iron-chelating agent.
Topics: 2,2'-Dipyridyl; Antineoplastic Combined Chemotherapy Protocols; Deferoxamine; Drug Synergism; Edetic | 1986 |
Acne urticata associated with chronic myelogenous leukemia.
Topics: Acne Vulgaris; Cimetidine; Diphenhydramine; Female; Histamine; Humans; Hydroxyurea; Leukemia, Myeloi | 1985 |
In vitro cytotoxicity of caracemide alone and in combination with hydroxyurea or iron-chelating agents in human chronic myeloid leukemia cells and murine tumors.
Topics: 2,2'-Dipyridyl; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chelating Ag | 1988 |
Hydroxyurea as a cause of drug fever in chronic myeloid leukaemia.
Topics: Drug Hypersensitivity; Fever; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged | 1988 |
Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia.
Topics: Adult; Bone Marrow; Cytarabine; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Philadelphia C | 1988 |
Enhancement by hemin of the sensitivity of K562 human leukemic cells to 1-beta-D-arabinofuranosylcytosine.
Topics: Aminolevulinic Acid; Butyrates; Cell Differentiation; Cell Line; Cytarabine; Daunorubicin; Deoxyguan | 1986 |
Cytofluorometric detection of chronic myelocytic leukemia supervening in a patient with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal; Antigens, Neoplasm; Chromosomes, Human, 21-22 and Y; Female; Flow Cyto | 1986 |
Histone mRNA degradation in vivo: the first detectable step occurs at or near the 3' terminus.
Topics: Base Sequence; Cell Line; Cloning, Molecular; Cytarabine; DNA Replication; Genes; Histones; Humans; | 1986 |
Augmentation of hydroxyurea cytotoxicity by sintamil in human chronic myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dibenzoxazepines; Drug Interactions; | 1986 |
[24-year survival in chronic myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Drug Administration Schedule; Female | 1987 |
Excretion of hydroxyurea into milk.
Topics: Adult; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Milk, Human; Spectrophotometry | 1987 |
Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia.
Topics: Adult; Aged; Antigen-Antibody Complex; Complement Activating Enzymes; Complement C1q; Complement C3; | 1986 |
Vindesine-prednisone in the treatment of blast crisis of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Administration Schedu | 1985 |
Increased leucocyte alkaline phosphatase and transcobalamin III in chronic myeloid leukaemia associated with lithium therapy.
Topics: Adult; Alkaline Phosphatase; Bipolar Disorder; Busulfan; Female; Humans; Hydroxyurea; Leukemia, Myel | 1985 |
Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistan | 1985 |
Cutaneous xanthomas associated with chronic myelomonocytic leukemia.
Topics: Adult; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Prednisone; Skin Diseases; Xanthomatosis | 1985 |
Hypercalcaemia in the accelerated phase of chronic myelogenous leukaemia: no relationship to the phenotype of the blast cells.
Topics: Adult; Bone Marrow Examination; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Hydroxyu | 1985 |
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Blood Cell Coun | 1985 |
Flow microfluorometric analysis of cell killing with cytotoxic drugs.
Topics: Autoanalysis; Bleomycin; Cell Division; Cell Line; Cell Survival; Cytarabine; Dactinomycin; Demecolc | 1974 |
Chemotherapy with hydroxyurea, leucopheresis and splenectomy in the treatment of chronic myeloid leukemia at the problastic phase.
Topics: Adolescent; Adult; Aged; Blood Transfusion; Child; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte | 1972 |
Treatment of the blastic phase of chronic myeloid leukaemia. A question to solve.
Topics: Adult; Antineoplastic Agents; Child; Cytarabine; Glycine; Humans; Hydroxyurea; Leukemia, Myeloid; Pu | 1972 |
[Preliminary studies on the effectiveness of the association cytosine-arabinoside, thioguanine, hydroxyureas in the treatment of blastic crisis in chronic myeloid leukemia].
Topics: Adult; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; | 1972 |
Splenectomy in early chronic myeloid leukaemia: preliminary report on 37 cases.
Topics: Adolescent; Adult; Blood Cell Count; Blood Platelets; Cytarabine; Death; Drug Therapy, Combination; | 1974 |
[Trial treatment of chronic myeloid leukemia with 3 new chemotherapeutic agents: dibromomannitol, hydroxyurea and desacetamidocolchicine].
Topics: Adult; Antineoplastic Agents; Colchicine; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Mann | 1966 |
[Survival in chronic myeloid leukemia following aplasia caused by Misulban].
Topics: Adult; Busulfan; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged | 1969 |
Combination chemotherapy of adult acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Cytarabine; Drug Synergism; Female; Humans; Hyd | 1972 |
Chronic myelocytic and chronic lymphocytic leukemia.
Topics: Age Factors; Antilymphocyte Serum; Antineoplastic Agents; Blood Cell Count; Busulfan; Chlorambucil; | 1972 |
Hydroxyurea, leucopheresis, and splenectomy in chronic myeloid leukaemia at the problastic phase.
Topics: Adolescent; Adult; Aged; Blood Transfusion; Busulfan; Demecolcine; Female; Humans; Hydroxyurea; Leuk | 1973 |
Daunorubicin-prednisone remission induction with hydroxyurea maintenance in acute non-lymphocytic leukemia.
Topics: Adult; Age Factors; Daunorubicin; Female; Humans; Hydroxyurea; Leukemia, Erythroblastic, Acute; Leuk | 1973 |
Optimism in leukemia treatment.
Topics: Acute Disease; Adult; Child; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia, | 1973 |
In-vitro sensitivity to cytostatics in chronic myeloid leukaemia.
Topics: Antibiotics, Antineoplastic; Busulfan; Cells, Cultured; Cytotoxicity Tests, Immunologic; Daunorubici | 1973 |
Proceedings: The chronic leukemias: current therapeutic concepts.
Topics: Bromine; Busulfan; Cell Division; Chlorambucil; Chromosome Aberrations; Cyclophosphamide; Humans; Hy | 1972 |
[Treatment of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Busulfan; Humans; Hydroxyurea; Leukemia, Myeloid; Phosphorus Radioisotopes | 1973 |
Management of priapism in patients with chronic granulocytic leukemia.
Topics: Adult; Anti-Bacterial Agents; Busulfan; Cytarabine; Diazepam; Humans; Hydroxyurea; Infusions, Parent | 1974 |
[Hepatic peliosis: possible etiologic role of medication].
Topics: Aged; Allopurinol; Chemical and Drug Induced Liver Injury; Humans; Hydroxyurea; Iatrogenic Disease; | 1973 |
Hydroxyurea its value in 50 cases of advanced cancers.
Topics: Adolescent; Adult; Humans; Hydroxyurea; Leukemia, Myeloid; Lymphoma; Male; Middle Aged; Mouth Neopla | 1973 |
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance.
Topics: Anemia; Azauridine; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Busulfan; Cell Trans | 1974 |
[Personal experience on the chemotherapy of leukemias and hematosarcomas].
Topics: Antineoplastic Agents; Drug Synergism; Hodgkin Disease; Humans; Hydrazines; Hydroxyurea; Leukemia; L | 1968 |
[Experiences in the treatment of chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged | 1971 |
A preliminary clinical evaluation of the therapeutic effects of hydroxyurea in patients with myelogenous leukaemia.
Topics: Adult; Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myeloid; Male | 1966 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; L | 1968 |
Hydroxyurea (Hydrea).
Topics: Humans; Hydroxyurea; Leukemia, Myeloid; Leukocytes; Melanoma | 1968 |
Lens changes in chronic granulocytic leukemia. Possible relationship to chemotherapy.
Topics: Adult; Age Factors; Aged; Bromides; Busulfan; Cataract; Colchicine; Humans; Hydroxyurea; Lens, Cryst | 1969 |
Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy.
Topics: Adult; Biological Clocks; Blood Cell Count; Blood Platelets; Female; Hemoglobinometry; Humans; Hydro | 1970 |
The treatment of chronic leukaemia.
Topics: Antibiotics, Antineoplastic; Busulfan; Chlorambucil; Cyclophosphamide; Female; Humans; Hydroxyurea; | 1970 |
Splenic irradiation following chemotherapy in chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Blood Platelets; Bone Marrow Diseases; Busulfan; Child; C | 1971 |
[Treatment of chronic myeloid leukemia with hydroxyurea].
Topics: Autoradiography; DNA, Neoplasm; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Middle Aged; Phagocy | 1971 |